Discovery of a multipotent chaperone, 1-(2,6-Difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol with the inhibitory effects on the proliferation of prion, cancer as well as influenza virus.


Journal

Prion
ISSN: 1933-690X
Titre abrégé: Prion
Pays: United States
ID NLM: 101472305

Informations de publication

Date de publication:
12 2020
Historique:
entrez: 24 1 2020
pubmed: 24 1 2020
medline: 1 10 2021
Statut: ppublish

Résumé

We previously discovered three carbazole derivatives, GJP14 (1-piperidinylmethyl-2-(1-oxo-6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)-ethan-1-ol) with anti-prion activity, GJC29 (benzylamino-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol) with anti-cancer activity, and THC19 (1-piperidinylmethyl-2-(1,2,3,4-tetrahydrocarnazol-9-yl)-ethan-1-ol) with anti-influenza virus activity. During optimization of GJP14 for the anti-prion activity, we discovered a compound, 1-(2,6-difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol, termed 5Y, had the most strong anti-prion activity among a series of newly synthesized derivatives. Intriguingly, we noticed that 5Y had also the most strong anti-colon cancer as well as the anti-influenza virus activities among derivatives. No significant toxicity of 5Y was observed. These results demonstrate that 5Y is a multipotent lead compound with unusually wide spectrum, and may be applicable to therapeutics targeting multiple diseases.

Identifiants

pubmed: 31971853
doi: 10.1080/19336896.2020.1714372
pmc: PMC6984644
doi:

Substances chimiques

Antineoplastic Agents 0
Carbazoles 0
Prion Proteins 0
carbazole 0P2197HHHN

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-46

Références

Antimicrob Agents Chemother. 2009 Feb;53(2):765-71
pubmed: 19015328
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11921-6
pubmed: 17616582
Cell Death Differ. 2017 Oct;24(10):1784-1798
pubmed: 28644435
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8438-42
pubmed: 10411893
J Pharmacol Exp Ther. 2006 May;317(2):562-70
pubmed: 16436501
Biochim Biophys Acta. 2012 Feb;1820(2):90-5
pubmed: 22108550
Proteins. 1995 Nov;23(3):403-14
pubmed: 8710833
Oncol Rep. 2009 Oct;22(4):739-44
pubmed: 19724851
Microbiol Immunol. 2007;51(7):661-9
pubmed: 17641468
Protein Sci. 2016 Dec;25(12):2132-2141
pubmed: 27595938
Bioorg Med Chem Lett. 2008 Jun 15;18(12):3517-21
pubmed: 18511277
Science. 1982 Dec 24;218(4579):1309-11
pubmed: 6815801
Protein Sci. 2013 Jan;22(1):22-34
pubmed: 23081827
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5
pubmed: 18650397
Nature. 1996 Jul 11;382(6587):180-2
pubmed: 8700211
Science. 1994 Apr 22;264(5158):530-1
pubmed: 7909169
Eur J Med Chem. 2011 Nov;46(11):5675-9
pubmed: 21906853
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82
pubmed: 15667143
J Am Chem Soc. 2012 May 23;134(20):8360-3
pubmed: 22574905
J Biol Chem. 2001 Dec 21;276(51):48231-6
pubmed: 11572854
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13937-42
pubmed: 11095725
Nat Biomed Eng. 2019 Mar;3(3):206-219
pubmed: 30948810
Microbes Infect. 2012 Aug;14(9):740-7
pubmed: 22441116
J Mol Recognit. 1996 Jan-Feb;9(1):1-5
pubmed: 8723313
Evid Based Complement Alternat Med. 2012;2012:946867
pubmed: 21876716

Auteurs

Satoshi Yamashita (S)

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.

Ryo Honda (R)

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.

Mayuko Fukuoka (M)

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.

Tsutomu Kimura (T)

Department of Chemistry, Faculty of Science Division II, Tokyo University of Science, Tokyo, Japan.

Junji Hosokawa-Muto (J)

First Department of Forsenic Science, National Research Institute of Police Science, Chiba, Japan.

Kazuo Kuwata (K)

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Department of Gene and Development, Graduate School of Medicine, Gifu University, Gifu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH